Terms: = Prostate cancer AND ITK, PSCTK2, 3702, Q08881, ENSG00000113263, EMT, MGC126258, LYK, MGC126257 AND Treatment
378 results:
1. Knockdown of growth differentiation factor-15 restrains prostate cancer through regulating MAPK/ERK signaling pathway.
Yang M; Guo M; Su C; Hao W; Xu Z
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):162-167. PubMed ID: 38650142
[TBL] [Abstract] [Full Text] [Related]
2. Targeting HOXA11-AS to mitigate prostate cancer via the glycolytic metabolism: In vitro and in vivo.
Zhang J; Li S; Zhang M; Wang Z; Xing Z
J Cell Mol Med; 2024 Apr; 28(8):e18227. PubMed ID: 38520207
[TBL] [Abstract] [Full Text] [Related]
3. Investigation of in-vitro Anti-cancer and Apoptotic Potential of Garlic-Derived Nanovesicles against prostate and Cervical cancer Cell Lines.
Sharma V; Sinha ES; Singh J
Asian Pac J Cancer Prev; 2024 Feb; 25(2):575-585. PubMed ID: 38415544
[TBL] [Abstract] [Full Text] [Related]
4. Co-expression of Twist and Snai1: predictor of poor prognosis and biomarker of treatment resistance in untreated prostate cancer.
Said R; Hernández-Losa J; Moline T; de Haro RSL; Zouari S; Blel A; Rammeh S; Derouiche A; Ouerhani S
Mol Biol Rep; 2024 Jan; 51(1):226. PubMed ID: 38281235
[TBL] [Abstract] [Full Text] [Related]
5. Harnessing function of emt in cancer drug resistance: a metastasis regulator determines chemotherapy response.
Ebrahimi N; Manavi MS; Faghihkhorasani F; Fakhr SS; Baei FJ; Khorasani FF; Zare MM; Far NP; Rezaei-Tazangi F; Ren J; Reiter RJ; Nabavi N; Aref AR; Chen C; Ertas YN; Lu Q
Cancer Metastasis Rev; 2024 Mar; 43(1):457-479. PubMed ID: 38227149
[TBL] [Abstract] [Full Text] [Related]
6. Serine/threonine kinase 36 induced epithelial-mesenchymal transition promotes docetaxel resistance in prostate cancer.
He T; Li NX; Pan ZJ; Zou ZH; Chen JC; Yu SZ; Lv F; Xie QC; Zou J
Sci Rep; 2024 Jan; 14(1):729. PubMed ID: 38184689
[TBL] [Abstract] [Full Text] [Related]
7. Novel signatures of prostate cancer progression and therapeutic resistance.
Wang J; Ben-David R; Mehrazin R; Yang W; Tewari AK; Kyprianou N
Expert Opin Ther Targets; 2023; 27(12):1195-1206. PubMed ID: 38108262
[TBL] [Abstract] [Full Text] [Related]
8. Synergistic effect of docetaxel combined with a novel multi-target inhibitor CUDC-101 on inhibiting human prostate cancer.
Li Z; Quan C; Li W; Ji M
Pathol Res Pract; 2023 Dec; 252():154938. PubMed ID: 37989076
[TBL] [Abstract] [Full Text] [Related]
9. Small extracellular vesicles: Non-negligible vesicles in tumor progression, diagnosis, and therapy.
Zhou X; Jia Y; Mao C; Liu S
Cancer Lett; 2024 Jan; 580():216481. PubMed ID: 37972701
[TBL] [Abstract] [Full Text] [Related]
10. Radiation therapy margin reduction for patients with localized prostate cancer: A prospective study of the dosimetric impact and quality of life.
Kumarasiri A; Chetty IJ; Devpura S; Pradhan D; Aref I; Elshaikh MA; Movsas B
J Appl Clin Med Phys; 2024 Mar; 25(3):e14198. PubMed ID: 37952248
[TBL] [Abstract] [Full Text] [Related]
11. The effect of Ganoderma lucidum polysaccharide extract on sensitizing prostate cancer cells to flutamide and docetaxel: an in vitro study.
Rahimnia R; Akbari MR; Yasseri AF; Taheri D; Mirzaei A; Ghajar HA; Farashah PD; Baghdadabad LZ; Aghamir SMK
Sci Rep; 2023 Nov; 13(1):18940. PubMed ID: 37919464
[TBL] [Abstract] [Full Text] [Related]
12. FOXS1 promotes prostate cancer progression through the Hedgehog/Gli1 pathway.
Wang M; Huang W
Biochem Pharmacol; 2023 Dec; 218():115893. PubMed ID: 37890593
[TBL] [Abstract] [Full Text] [Related]
13. Aridanin and oleanane-3- O-β-D-glucoside-2'-acetamide obtained from Tetrapleura tetraptera (Schumach. & Thonn) Taub. (Fabaceae) induces potent apoptotic activity in human prostate cancer cells.
Kamdem MHK; Zingue S; Grein T; Maxeiner S; Rutz J; Mmutlane EM; Njamen D; Blaheta RA; Ndinteh DT
J Ethnopharmacol; 2024 Jan; 319(Pt 3):117298. PubMed ID: 37866463
[TBL] [Abstract] [Full Text] [Related]
14. US-guided EM tracked system for HDR brachytherapy: A first in-men randomized study for whole prostate treatment.
Lavallee MC; Cantin A; Aubin S; Lefebvre M; Marrier AS; Bouchard I; Fiset C; Villeneuve-Gauthier A; Foster W; Martin AG; Carignan D; Beaulieu L; Vigneault E
Brachytherapy; 2024; 23(1):64-72. PubMed ID: 37806788
[TBL] [Abstract] [Full Text] [Related]
15. prostate cancer therapy outcome prediction: are miRNAs a suitable guide for therapeutic decisions?
Konoshenko M; Laktionov P; Bryzgunova O
Andrology; 2024 May; 12(4):705-718. PubMed ID: 37750354
[TBL] [Abstract] [Full Text] [Related]
16. AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer.
Yin L; Ye Y; Zou L; Lin J; Dai Y; Fu Y; Liu Y; Peng Y; Gao Y; Fu Y; Qi X; Deng T; Zhang S; Li X
J Exp Clin Cancer Res; 2023 Aug; 42(1):204. PubMed ID: 37563661
[TBL] [Abstract] [Full Text] [Related]
17. A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer.
Mourkioti I; Polyzou A; Veroutis D; Theocharous G; Lagopati N; Gentile E; Stravokefalou V; Thanos DF; Havaki S; Kletsas D; Panaretakis T; Logothetis CJ; Stellas D; Petty R; Blandino G; Papaspyropoulos A; Gorgoulis VG
J Exp Clin Cancer Res; 2023 Jul; 42(1):187. PubMed ID: 37507762
[TBL] [Abstract] [Full Text] [Related]
18. PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.
Rezaei S; Nikpanjeh N; Rezaee A; Gholami S; Hashemipour R; Biavarz N; Yousefi F; Tashakori A; Salmani F; Rajabi R; Khorrami R; Nabavi N; Ren J; Salimimoghadam S; Rashidi M; Zandieh MA; Hushmandi K; Wang Y
Eur J Pharmacol; 2023 Sep; 955():175909. PubMed ID: 37490949
[TBL] [Abstract] [Full Text] [Related]
19. Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant prostate cancers.
Mitra Ghosh T; Mazumder S; Davis J; Yadav J; Akinpelu A; Alnaim A; Kumar H; Waliagha R; Church Bird AE; Rais-Bahrami S; Bird RC; Mistriotis P; Mishra A; Yates CC; Mitra AK; Arnold RD
Cancer Res Commun; 2023 Jul; 3(7):1286-1311. PubMed ID: 37476073
[TBL] [Abstract] [Full Text] [Related]
20. Downregulation of EZH2 inhibits epithelial-mesenchymal transition in enzalutamide-resistant prostate cancer.
Zhang Z; Wang X; Kim M; He D; Wang C; Fong KW; Liu X
Prostate; 2023 Nov; 83(15):1458-1469. PubMed ID: 37475584
[TBL] [Abstract] [Full Text] [Related]
[Next]